Efficacy of cadonilimab and anlotinib combination in treating multiple drug‑resistant pulmonary large cell neuroendocrine carcinoma: A case report and literature review
Pulmonary large cell neuroendocrine carcinoma (LCNEC) has a poor prognosis, and there is no consensus on optimal treatment strategies for pulmonary LCNEC. Certain patients with pulmonary LCNEC may benefit from targeted and traditional programmed cell death protein-1 (PD-1) monoclonal antibody therap...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2025-01, Vol.29 (1), p.27, Article 27 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 27 |
| container_title | Oncology letters |
| container_volume | 29 |
| creator | Qin, Xi Liu, Yulan Zhu, Lin Xu, Lieyin Lv, Jinfu Mo, Yunyan Kang, Mafei Xue, Feng |
| description | Pulmonary large cell neuroendocrine carcinoma (LCNEC) has a poor prognosis, and there is no consensus on optimal treatment strategies for pulmonary LCNEC. Certain patients with pulmonary LCNEC may benefit from targeted and traditional programmed cell death protein-1 (PD-1) monoclonal antibody therapies, however, for most patients, only a few drugs are effective after chemotherapy. The present report describes the case of a 68-year-old man with advanced pulmonary LCNEC treated with cadonilimab and anlotinib after becoming resistant to PD-1 monoclonal antibody therapy and multiple chemotherapies. Computed tomography was used to evaluate treatment response. The treatment was efficacious and met the partial response criteria after three treatment cycles, and the coughing and dyspnea resolved. The primary mass and lymph node metastases continued to shrink after five treatment cycles. Therefore, the present case report suggests that a combination of cadonilimab and anlotinib is a potential treatment strategy for patients with pulmonary LCNEC. |
| doi_str_mv | 10.3892/ol.2024.14773 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11542163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3134600259</sourcerecordid><originalsourceid>FETCH-LOGICAL-c302t-b7e2047c1a1a9c988ba19e94e6a57790342034d3e9f3d948c6c671c0bb2805fe3</originalsourceid><addsrcrecordid>eNpVUctqFUEQHUQxIcnSrTS4nmu_5tFuJIREhYCbuG56emquHXq6x-qeyN3lF_wNPytfYt8kXrSgqNfhVFGnqt4wuhG94u-j33DK5YbJrhMvqmPWKV4z2vOXh7yTR9VZSre0WNOyvm9fV0dCNYxLpY6r35fT5KyxOxInYs0Yg_NuNgMxYSzuY3bBDcTGeXDBZBcDcYFkhJKHLZlXn93igYy4bh_ufyEkl7IJmSyrn2MwuCPe4BaIBe9JgBUjhDFadKH0DFoX4mw-kPNSJCAIS8T8uNy7DGjyivvunYOfp9WryfgEZ8_xpPp2dXlz8bm-_vrpy8X5dW0F5bkeOuBUdpYZZpRVfT8YpkBJaE3TdYoKyYuPAtQkRiV729q2Y5YOA-9pM4E4qT4-8S7rMMNoIWQ0Xi9Y_oI7HY3T_0-C-6638U4z1kjOWlEY3j0zYPyxQsr6Nq4YytFaMCFbSnmjCqp-QlmMKSFMhxWM6r28Onq9l1c_ylvwb_-964D-K6b4Aw18pmw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3134600259</pqid></control><display><type>article</type><title>Efficacy of cadonilimab and anlotinib combination in treating multiple drug‑resistant pulmonary large cell neuroendocrine carcinoma: A case report and literature review</title><source>PubMed Central</source><creator>Qin, Xi ; Liu, Yulan ; Zhu, Lin ; Xu, Lieyin ; Lv, Jinfu ; Mo, Yunyan ; Kang, Mafei ; Xue, Feng</creator><creatorcontrib>Qin, Xi ; Liu, Yulan ; Zhu, Lin ; Xu, Lieyin ; Lv, Jinfu ; Mo, Yunyan ; Kang, Mafei ; Xue, Feng</creatorcontrib><description>Pulmonary large cell neuroendocrine carcinoma (LCNEC) has a poor prognosis, and there is no consensus on optimal treatment strategies for pulmonary LCNEC. Certain patients with pulmonary LCNEC may benefit from targeted and traditional programmed cell death protein-1 (PD-1) monoclonal antibody therapies, however, for most patients, only a few drugs are effective after chemotherapy. The present report describes the case of a 68-year-old man with advanced pulmonary LCNEC treated with cadonilimab and anlotinib after becoming resistant to PD-1 monoclonal antibody therapy and multiple chemotherapies. Computed tomography was used to evaluate treatment response. The treatment was efficacious and met the partial response criteria after three treatment cycles, and the coughing and dyspnea resolved. The primary mass and lymph node metastases continued to shrink after five treatment cycles. Therefore, the present case report suggests that a combination of cadonilimab and anlotinib is a potential treatment strategy for patients with pulmonary LCNEC.</description><identifier>ISSN: 1792-1074</identifier><identifier>EISSN: 1792-1082</identifier><identifier>DOI: 10.3892/ol.2024.14773</identifier><identifier>PMID: 39512499</identifier><language>eng</language><publisher>Greece: Spandidos Publications UK Ltd</publisher><subject>Cancer therapies ; Case Report ; Case reports ; Cell death ; Chemotherapy ; Drug dosages ; Dyspnea ; Fistula ; Iodine ; Kinases ; Lung cancer ; Lymphatic system ; Medical prognosis ; Metastasis ; Monoclonal antibodies ; Mutation ; Patients ; Tumors</subject><ispartof>Oncology letters, 2025-01, Vol.29 (1), p.27, Article 27</ispartof><rights>Copyright: © 2024 Qin et al.</rights><rights>Copyright Spandidos Publications UK Ltd. 2025</rights><rights>Copyright: © 2024 Qin et al. 2024</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c302t-b7e2047c1a1a9c988ba19e94e6a57790342034d3e9f3d948c6c671c0bb2805fe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542163/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542163/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39512499$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qin, Xi</creatorcontrib><creatorcontrib>Liu, Yulan</creatorcontrib><creatorcontrib>Zhu, Lin</creatorcontrib><creatorcontrib>Xu, Lieyin</creatorcontrib><creatorcontrib>Lv, Jinfu</creatorcontrib><creatorcontrib>Mo, Yunyan</creatorcontrib><creatorcontrib>Kang, Mafei</creatorcontrib><creatorcontrib>Xue, Feng</creatorcontrib><title>Efficacy of cadonilimab and anlotinib combination in treating multiple drug‑resistant pulmonary large cell neuroendocrine carcinoma: A case report and literature review</title><title>Oncology letters</title><addtitle>Oncol Lett</addtitle><description>Pulmonary large cell neuroendocrine carcinoma (LCNEC) has a poor prognosis, and there is no consensus on optimal treatment strategies for pulmonary LCNEC. Certain patients with pulmonary LCNEC may benefit from targeted and traditional programmed cell death protein-1 (PD-1) monoclonal antibody therapies, however, for most patients, only a few drugs are effective after chemotherapy. The present report describes the case of a 68-year-old man with advanced pulmonary LCNEC treated with cadonilimab and anlotinib after becoming resistant to PD-1 monoclonal antibody therapy and multiple chemotherapies. Computed tomography was used to evaluate treatment response. The treatment was efficacious and met the partial response criteria after three treatment cycles, and the coughing and dyspnea resolved. The primary mass and lymph node metastases continued to shrink after five treatment cycles. Therefore, the present case report suggests that a combination of cadonilimab and anlotinib is a potential treatment strategy for patients with pulmonary LCNEC.</description><subject>Cancer therapies</subject><subject>Case Report</subject><subject>Case reports</subject><subject>Cell death</subject><subject>Chemotherapy</subject><subject>Drug dosages</subject><subject>Dyspnea</subject><subject>Fistula</subject><subject>Iodine</subject><subject>Kinases</subject><subject>Lung cancer</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Mutation</subject><subject>Patients</subject><subject>Tumors</subject><issn>1792-1074</issn><issn>1792-1082</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpVUctqFUEQHUQxIcnSrTS4nmu_5tFuJIREhYCbuG56emquHXq6x-qeyN3lF_wNPytfYt8kXrSgqNfhVFGnqt4wuhG94u-j33DK5YbJrhMvqmPWKV4z2vOXh7yTR9VZSre0WNOyvm9fV0dCNYxLpY6r35fT5KyxOxInYs0Yg_NuNgMxYSzuY3bBDcTGeXDBZBcDcYFkhJKHLZlXn93igYy4bh_ufyEkl7IJmSyrn2MwuCPe4BaIBe9JgBUjhDFadKH0DFoX4mw-kPNSJCAIS8T8uNy7DGjyivvunYOfp9WryfgEZ8_xpPp2dXlz8bm-_vrpy8X5dW0F5bkeOuBUdpYZZpRVfT8YpkBJaE3TdYoKyYuPAtQkRiV729q2Y5YOA-9pM4E4qT4-8S7rMMNoIWQ0Xi9Y_oI7HY3T_0-C-6638U4z1kjOWlEY3j0zYPyxQsr6Nq4YytFaMCFbSnmjCqp-QlmMKSFMhxWM6r28Onq9l1c_ylvwb_-964D-K6b4Aw18pmw</recordid><startdate>20250101</startdate><enddate>20250101</enddate><creator>Qin, Xi</creator><creator>Liu, Yulan</creator><creator>Zhu, Lin</creator><creator>Xu, Lieyin</creator><creator>Lv, Jinfu</creator><creator>Mo, Yunyan</creator><creator>Kang, Mafei</creator><creator>Xue, Feng</creator><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20250101</creationdate><title>Efficacy of cadonilimab and anlotinib combination in treating multiple drug‑resistant pulmonary large cell neuroendocrine carcinoma: A case report and literature review</title><author>Qin, Xi ; Liu, Yulan ; Zhu, Lin ; Xu, Lieyin ; Lv, Jinfu ; Mo, Yunyan ; Kang, Mafei ; Xue, Feng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c302t-b7e2047c1a1a9c988ba19e94e6a57790342034d3e9f3d948c6c671c0bb2805fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Cancer therapies</topic><topic>Case Report</topic><topic>Case reports</topic><topic>Cell death</topic><topic>Chemotherapy</topic><topic>Drug dosages</topic><topic>Dyspnea</topic><topic>Fistula</topic><topic>Iodine</topic><topic>Kinases</topic><topic>Lung cancer</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Mutation</topic><topic>Patients</topic><topic>Tumors</topic><toplevel>online_resources</toplevel><creatorcontrib>Qin, Xi</creatorcontrib><creatorcontrib>Liu, Yulan</creatorcontrib><creatorcontrib>Zhu, Lin</creatorcontrib><creatorcontrib>Xu, Lieyin</creatorcontrib><creatorcontrib>Lv, Jinfu</creatorcontrib><creatorcontrib>Mo, Yunyan</creatorcontrib><creatorcontrib>Kang, Mafei</creatorcontrib><creatorcontrib>Xue, Feng</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qin, Xi</au><au>Liu, Yulan</au><au>Zhu, Lin</au><au>Xu, Lieyin</au><au>Lv, Jinfu</au><au>Mo, Yunyan</au><au>Kang, Mafei</au><au>Xue, Feng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of cadonilimab and anlotinib combination in treating multiple drug‑resistant pulmonary large cell neuroendocrine carcinoma: A case report and literature review</atitle><jtitle>Oncology letters</jtitle><addtitle>Oncol Lett</addtitle><date>2025-01-01</date><risdate>2025</risdate><volume>29</volume><issue>1</issue><spage>27</spage><pages>27-</pages><artnum>27</artnum><issn>1792-1074</issn><eissn>1792-1082</eissn><abstract>Pulmonary large cell neuroendocrine carcinoma (LCNEC) has a poor prognosis, and there is no consensus on optimal treatment strategies for pulmonary LCNEC. Certain patients with pulmonary LCNEC may benefit from targeted and traditional programmed cell death protein-1 (PD-1) monoclonal antibody therapies, however, for most patients, only a few drugs are effective after chemotherapy. The present report describes the case of a 68-year-old man with advanced pulmonary LCNEC treated with cadonilimab and anlotinib after becoming resistant to PD-1 monoclonal antibody therapy and multiple chemotherapies. Computed tomography was used to evaluate treatment response. The treatment was efficacious and met the partial response criteria after three treatment cycles, and the coughing and dyspnea resolved. The primary mass and lymph node metastases continued to shrink after five treatment cycles. Therefore, the present case report suggests that a combination of cadonilimab and anlotinib is a potential treatment strategy for patients with pulmonary LCNEC.</abstract><cop>Greece</cop><pub>Spandidos Publications UK Ltd</pub><pmid>39512499</pmid><doi>10.3892/ol.2024.14773</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2025-01, Vol.29 (1), p.27, Article 27 |
| issn | 1792-1074 1792-1082 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11542163 |
| source | PubMed Central |
| subjects | Cancer therapies Case Report Case reports Cell death Chemotherapy Drug dosages Dyspnea Fistula Iodine Kinases Lung cancer Lymphatic system Medical prognosis Metastasis Monoclonal antibodies Mutation Patients Tumors |
| title | Efficacy of cadonilimab and anlotinib combination in treating multiple drug‑resistant pulmonary large cell neuroendocrine carcinoma: A case report and literature review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T03%3A47%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20cadonilimab%20and%20anlotinib%20combination%20in%20treating%20multiple%20drug%E2%80%91resistant%20pulmonary%20large%20cell%20neuroendocrine%20carcinoma:%20A%20case%20report%20and%20literature%20review&rft.jtitle=Oncology%20letters&rft.au=Qin,%20Xi&rft.date=2025-01-01&rft.volume=29&rft.issue=1&rft.spage=27&rft.pages=27-&rft.artnum=27&rft.issn=1792-1074&rft.eissn=1792-1082&rft_id=info:doi/10.3892/ol.2024.14773&rft_dat=%3Cproquest_pubme%3E3134600259%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3134600259&rft_id=info:pmid/39512499&rfr_iscdi=true |